All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
How could new treatment options improve outcomes in FLT3-mutated AML?
By Erika Roa
Featured
Bookmark this article
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment options improve outcomes in FLT3-mutated acute myeloid leukemia (AML)?
How could new treatment options improve outcomes in FLT3-mutated AML?
Daver begins by outlining the nature of FLT3 mutations in patients with AML, including their association with a higher-risk prognosis, before discussing first- and second-generation FLT3 inhibitors and the studies that explored these. Daver goes on to outline a study on a venetoclax + gilteritinib combination in relapsed/refractory FLT3-mutated AML and its promising efficacy. Finally, Daver discusses studies aiming to improve outcomes for different patient groups, utilizing varying dosages and therapeutic combinations.
Your opinion matters
28 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox